Chemotherapy-Induced Cutaneous Sclerosis: A Rare Clinical Finding.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Scleroderma-like cutaneous sclerosis is a rare adverse drug reaction.
• Paclitaxel and its formulations are associated with this reaction in cancer patients.
• The condition typically affects the lower limbs and can be refractory to treatment.

Observation:

• A patient receiving chemotherapy with nab-paclitaxel and gemcitabine developed severe cutaneous sclerosis.
• The skin hardening presented as a rare adverse reaction to the prescribed chemotherapy regimen.
• The condition was resistant to standard treatment modalities.

Findings:

• The severe cutaneous sclerosis did not respond to treatment.
• The adverse reaction led to the discontinuation of the patient's chemotherapy.
• This case underscores the potential for severe, refractory skin toxicity from specific chemotherapeutic agents.

Implications:

• Clinicians should be vigilant for scleroderma-like skin reactions during paclitaxel-based chemotherapy.
• Management strategies for chemotherapy-induced cutaneous sclerosis require further investigation.
• Understanding and managing rare adverse drug reactions is crucial for optimizing cancer patient care and treatment adherence.